导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.54% | 4113/4773 |
| 近一周 | -5.53% | 5300/5462 |
| 近一月 | -1.40% | 936/5421 |
| 近一季 | -1.93% | 1101/5209 |
| 近半年 | -13.93% | 3884/4920 |
| 近一年 | -19.18% | 3902/4366 |
| 近两年 | 4.41% | 2837/2954 |
| 近三年 | -22.44% | 2174/2253 |
| 成立以来 | 18.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.80% 4190/4961 |
-15.62% 4685/5312 |
- - |
- - |
| 2025 | 2.24% 3197/4813 |
-3.55% 3062/3635 |
2.56% 1489/4076 |
3.81% 3719/4524 |
-0.44% 2497/4813 |
| 2024 | -2.72% 2201/3463 |
-5.25% 1858/2808 |
-6.57% 1979/3014 |
13.33% 2191/3129 |
-3.03% 2236/3463 |
| 2023 | -14.80% 1620/2656 |
3.11% 1262/2280 |
-9.80% 2071/2385 |
-2.50% 684/2515 |
-6.04% 1603/2655 |
| 2022 | -9.22% 170/2207 |
-9.72% 337/1919 |
4.35% 1019/2016 |
-9.63% 292/2113 |
6.63% 354/2208 |
| 2021 | 10.75% 419/1822 |
-8.45% 1085/1255 |
11.81% 360/1330 |
-3.48% 642/1466 |
12.09% 84/1822 |
| 2020 | 41.44% 290/1250 |
1.01% 152/1028 |
15.56% 486/1067 |
11.34% 459/1164 |
8.83% 658/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 方正富邦消费红利指数增强(LOF) VS. 长安沪深300非周期A(740101) |